Dravet syndrome is a rare and severe type of epilepsy that emerges in infancy. A number of genetic mutations that prevent cells from making key proteins can cause Dravet syndrome.

There is currently no cure for Dravet syndrome, but there are treatments to manage symptoms and slow disease progression.

Researchers are working on a number of experimental treatments for Dravet syndrome and to more effectively control seizures.

Ataluren

Ataluren is an experimental therapy that PTC Therapeutics is developing to treat Dravet syndrome. This medication is already marketed under the brand name Translarna to treat Duchenne muscular dystrophy within the European Union, Iceland, Liechtenstein, Norway, Israel, and South Korea.

Ataluren works by causing the machinery that makes protein to “read-through” gene mutations that would lead to the production of a faulty protein. By helping overcome these errors, the medications may be able to reduce the symptoms of Dravet syndrome.

An ongoing Phase 2 clinical trial (NCT02758626) is testing the safety and effectiveness of Ataluren in 16 patients with drug-resistant Dravet syndrome. Researchers expect to conclude the study in 2022.

EPX-100

EPX-100 was used as an antihistamine in the 1950s and 1960s. Researchers identified it in a screen of thousands of approved medications that they conducted in a zebrafish model of Dravet syndrome. They don’t fully understand the exact mechanism of how the compound works in treating Dravet syndrome. Epygenix Therapeutics is developing EPX-100. 

A placebo-controlled, double-blind, two-part Phase 1 clinical trial (NCT04069689) tested the safety and pharmacokinetics (a drug’s movement in the body) of oral EPX-100 in 24 healthy volunteers. Epygenix announced in January 2020 that the study results showed EPX-100 was safe and that both male and female volunteers tolerated it well. The company is preparing Phase 2 efficacy studies to test EPX-100 in patients with Dravet syndrome in the U.S. and Australia.

EPX-200

EPX-200 is a weight-loss compound that researchers identified in the same screen as EPX-100. Epygenix is testing the medication in preclinical studies.

Researchers also tested the experimental treatment off-label in five children with severe Dravet syndrome under the U.S. Food and Drug Administration (FDA) compassionate use program. The study showed that all five patients had fewer seizures while taking the compound. Researchers reported no severe side effects.

EPX-300

EPX-300 is another compound that researchers identified in the same screen as EPX-100 and EPX-200. The medication is approved to treat insomnia, depression, and anxiety. Epygenix is developing the EPX-300 to treat Dravet syndrome, which the FDA granted orphan drug designation.

Researchers do not yet know the mechanism of how EPX-300 may benefit Dravet syndrome.

Soticlestat

Soticlestat (previously TAK-935 or OV935) is an experimental therapy that Takeda Pharmaceuticals is developing in collaboration with Ovid Therapeutics to treat rare developmental and epileptic encephalopathies (DEE), including Dravet syndrome. The FDA granted soticlestat orphan drug status in 2017.

The medication works by inhibiting the activity of the cholesterol 24-hydroxylase (CH24H) enzyme, which plays a role in regulating the neurotransmitter glutamate, which can increase the initiation and spread of seizure activity.

Two Phase 1 clinical trials (NCT02201056, NCT02539134) have tested the safety and pharmacokinetics of soticlestat in healthy volunteers. They showed the medication was safe and well-tolerated.

A multicenter Phase 1b/2a clinical trial (NCT03166215) studied the safety and tolerability of soticlestat in 18 patients with rare epileptic disorders, including Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. This study also demonstrated that soticlestat was safe and well-tolerated.

Ovid and Takeda are conducting a Phase 2 extension study called ENDYMION (NCT03635073) to assess the long-term safety and tolerability of soticlestat in patients with Dravet syndrome, Lennox-Gastaut syndrome, Dup15q syndrome, and CDKL5 deficiency disorder. The trial is still recruiting participants in the U.S., Australia, China, Israel, Poland, and Spain. Researchers expect to complete it in April 2023.

SPN-817

SPN-817 (previously BIS-001) a treatment that Supernus Pharmaceuticals is developing. It is a synthetic form of a naturally occurring compound, huperzine A, which inhibits an enzyme in the brain that metabolizes neurotransmitters. 

SPN-817 is able to increase the levels of a neurotransmitter called gamma-aminobutyric acid (GABA). Researchers think this can reduce seizure activity in the brain.

An open-label Phase 1b trial (NCT03156439) tested the safety, tolerability, and pharmacokinetics of SPN-817. 

 

Last updated: July 24, 2020

***

Dravet Syndrome News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Sedef Iskit is a molecular biologist with a PhD in molecular oncology. She is writing informative medical articles for doctors and patients to pursue her strong interest in science education and communication.
Total Posts: 0
Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
×
Sedef Iskit is a molecular biologist with a PhD in molecular oncology. She is writing informative medical articles for doctors and patients to pursue her strong interest in science education and communication.